ACADIA Pharmaceuticals Inc. (ACAD): Price and Financial Metrics
ACAD Price/Volume Stats
| Current price | $21.98 | 52-week high | $25.23 |
| Prev. close | $21.34 | 52-week low | $13.40 |
| Day low | $21.47 | Volume | 1,280,000 |
| Day high | $22.10 | Avg. volume | 2,310,237 |
| 50-day MA | $17.38 | Dividend yield | N/A |
| 200-day MA | $17.03 | Market Cap | 3.68B |
ACAD Stock Price Chart Interactive Chart >
ACADIA Pharmaceuticals Inc. (ACAD) Company Bio
Acadia Pharmaceuticals Inc is a biotechnology company which develops and commercializes biopharmaceutical products to address central nervous system disorders. The firm aims to discover small molecule drugs to address Parkinson's, Alzheimer's and schizophrenia. The company was founded in 1993 by Mark Brann, PhD., a professor at the University of Vermont, under the name Receptor Technologies. By 1997, the company established its headquarters in San Diego, California and changed its name to Acadia Pharmaceuticals Inc and currently employs over 400 people. Since 2015, Stephen R. Davis serves as Acadia’s Chief Executive Officer and member of the board of directors. Competition for Acadia includes Otsuka Pharmaceutical Co., Ltd., H. Lundbeck A/S, and off-label branded and generic antipsychotics.
ACAD Latest News Stream
| Event/Time | News Detail | ||||||||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
ACAD Price Returns
| 1-mo | 29.83% |
| 3-mo | 25.17% |
| 6-mo | 17.16% |
| 1-year | 47.62% |
| 3-year | 21.30% |
| 5-year | -53.04% |
| YTD | 19.78% |
| 2024 | -41.39% |
| 2023 | 96.67% |
| 2022 | -31.79% |
| 2021 | -56.34% |
| 2020 | 24.96% |